Abstract 848P
Background
This observational real-world study used propensity score matching (PSM) to compare tumor lysis syndrome (TLS) associated mortality in patients (pts) with hematological malignancies who received either rasburicase or allopurinol monotherapy. Goldman/Cairo previously published that rasburicase significantly, more rapidly reduces uric acid exposure (AUC) compared to allopurinol in pts with/at risk of TLS.
Methods
In 2021, 266 oncologists provided anonymized data for 715 liquid tumor pts treated in past year for hyperuricemia (HU) risk and TLS potential. Out of 715, 282 rasburicase and allopurinol pts without spontaneous TLS or TLS before HU treatment (Tx) were matched using 11 pre-HU Tx covariates: acute renal failure, age, anti-cancer Tx, creatinine, gender, LDH, perceived risk, renal disease, tumor type, uric acid, and white blood cells. Matched pts met 1:1, nearest neighbor, caliper matching requirements (width=0.2) of standard deviation of logit of the PSM (d score) on covariates, regardless of whether pts later developed TLS post-HU Tx. Assessments include mean uric acid (UA) levels, anti-cancer Tx, and, as feasible, timing of death relative to HU Tx.
Results
The PSM was almost 0.6 before and near 0 after matching; no covariate had a large imbalance (│d│>0.25) before and after. Of 141 pts in each pt group, TLS-associated mortality was significantly less likely among rasburicase pts (2.1% [n = 3] vs. 7.1% [n = 10], P = 0.047) (71% reduction). Of 63 pt subset who developed TLS after HU Tx, TLS-associated fatalities were even less likely among rasburicase vs. allopurinol pts (8.3% [n = 3] vs. 37% [n = 10], P = 0.005). Comparing 13 who died vs. 269 who lived, no significant difference in mean UA was found (13.5 mg/dL vs. 11.4, respectively). Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone regimen (R-CHOP) was the predominant Tx among those who did not die (15%, n = 41). Only 1/13 pts died of R-CHOP. Seven pts died within 2 weeks of allopurinol (n = 6) or rasburicase (n = 1) monotherapy (timing not established for other 6).
Conclusions
PSM corrects before and after overall covariate and individual baseline covariate imbalances and rasburicase compared with allopurinol significantly reducing TLS-associated mortality.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Sanofi.
Disclosure
J.R. Gallagher, S. Carroll: Financial Interests, Full or part-time Employment: Clarity Pharma. E.J. Drea, Y.J. Barnes, C. Clark: Financial Interests, Stocks/Shares: Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
842P - Multicenter real-world study of newly diagnosed advanced-stage extranodal natural killer/T cell lymphoma (ENKTL): Proposal for intensive therapy
Presenter: Yu-Ce Wei
Session: Poster session 18
844P - Progression -free survival prediction of multiple myeloma patients in five European countries using machine learning models
Presenter: Maria Luisa Pleguezuelo Witte
Session: Poster session 18
845P - A machine learning based clinical platform for cancer subtyping and data integration in hematological malignancies
Presenter: Michelle Tang
Session: Poster session 18
846P - Artificial intelligence-driven identification of onco-hematology patients who may develop severe COVID-19
Presenter: Souad Assaad
Session: Poster session 18
847P - Fatal infections among leukemia patients
Presenter: Huijie Zhou
Session: Poster session 18
849P - Long non-coding RNA signatures and their role in the progression of childhood T cell acute lymphoblastic leukemia
Presenter: Pankaj Sharma
Session: Poster session 18
850P - A zebrafish model of MYC-driven acute myeloid leukemia reveals that neutrophil resistance to oncogenic transformation depends on their ability to promote PP2A-mediated MYC proteasomal degradation
Presenter: Anna Maria Luciano
Session: Poster session 18
851P - Characterization of a zebrafish model of MYC-driven acute myeloid leukemia
Presenter: Anna Maria Luciano
Session: Poster session 18
852P - c-MAF-driven metabolic reprogramming mediates H3K27 hyperacetylation to regulate super enhancer-associated genes
Presenter: Phyllis SY Chong
Session: Poster session 18
946P - Sintilimab plus lenvatinib as conversion therapy in patients with unresectable hepatocellular carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study
Presenter: Shichun Lu
Session: Poster session 18